JP2012176978A5 - - Google Patents

Download PDF

Info

Publication number
JP2012176978A5
JP2012176978A5 JP2012128849A JP2012128849A JP2012176978A5 JP 2012176978 A5 JP2012176978 A5 JP 2012176978A5 JP 2012128849 A JP2012128849 A JP 2012128849A JP 2012128849 A JP2012128849 A JP 2012128849A JP 2012176978 A5 JP2012176978 A5 JP 2012176978A5
Authority
JP
Japan
Prior art keywords
peptide
seq
pharmaceutical composition
carrier
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012128849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012176978A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012176978A publication Critical patent/JP2012176978A/ja
Publication of JP2012176978A5 publication Critical patent/JP2012176978A5/ja
Pending legal-status Critical Current

Links

JP2012128849A 2002-04-22 2012-06-06 プロテインキナーゼｃのペプチドインヒビター Pending JP2012176978A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37453002P 2002-04-22 2002-04-22
US60/374,530 2002-04-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003586176A Division JP2005523326A (ja) 2002-04-22 2003-04-22 プロテインキナーゼｃのペプチドインヒビター

Publications (2)

Publication Number Publication Date
JP2012176978A JP2012176978A (ja) 2012-09-13
JP2012176978A5 true JP2012176978A5 (enExample) 2013-04-18

Family

ID=29251202

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2003586177A Pending JP2005527209A (ja) 2002-04-22 2003-04-22 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2003586176A Withdrawn JP2005523326A (ja) 2002-04-22 2003-04-22 プロテインキナーゼｃのペプチドインヒビター
JP2009010402A Pending JP2009091372A (ja) 2002-04-22 2009-01-20 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2009011456A Pending JP2009102392A (ja) 2002-04-22 2009-01-21 プロテインキナーゼｃのペプチドインヒビター
JP2012128849A Pending JP2012176978A (ja) 2002-04-22 2012-06-06 プロテインキナーゼｃのペプチドインヒビター

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2003586177A Pending JP2005527209A (ja) 2002-04-22 2003-04-22 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2003586176A Withdrawn JP2005523326A (ja) 2002-04-22 2003-04-22 プロテインキナーゼｃのペプチドインヒビター
JP2009010402A Pending JP2009091372A (ja) 2002-04-22 2009-01-20 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2009011456A Pending JP2009102392A (ja) 2002-04-22 2009-01-21 プロテインキナーゼｃのペプチドインヒビター

Country Status (6)

Country Link
US (8) US7393835B2 (enExample)
EP (3) EP1501533A4 (enExample)
JP (5) JP2005527209A (enExample)
AU (4) AU2003234186B2 (enExample)
CA (3) CA2481512C (enExample)
WO (2) WO2003089457A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393835B2 (en) 2002-04-22 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
AU2003241559A1 (en) * 2003-05-16 2004-12-13 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
AU2003264918A1 (en) * 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) * 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
EP1699813A2 (en) * 2003-12-11 2006-09-13 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US20100041597A1 (en) 2005-08-05 2010-02-18 Jenny Phipps Peptides targeted to protein kinase c isoforms and uses thereof
WO2007025286A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
CA2644089A1 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
US20100279944A1 (en) * 2006-03-30 2010-11-04 Ronald Mathison Suppression and treatment of neuropathic pain
WO2007143119A2 (en) * 2006-06-01 2007-12-13 The Board Of Trustees Of The Leland Stanford Junior University Method of preventing progression of hypertension-induced heart failure with pkc peptides
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US8017583B2 (en) 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
EP2144615A4 (en) * 2007-04-06 2011-02-16 Kai Pharmaceuticals Inc METHOD OF USE OF GAMMA INHIBITOR COMPOUNDS FOR PAIN LIFTING
WO2008154004A2 (en) * 2007-06-07 2008-12-18 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of tumor metastases using protein kinase c (pkc) inhibitors
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
ES2703571T3 (es) * 2008-03-27 2019-03-11 Nestec Sa Métodos para aumentar la absorción de péptidos, peptidomiméticos y otros sustratos de proteína de transporte gastrointestinal
WO2010019965A1 (en) * 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
EP2398897B1 (en) 2009-02-20 2017-06-28 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
CN102388130B (zh) 2009-02-27 2014-08-27 细胞动力国际有限公司 多能细胞的分化
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
WO2010111533A2 (en) * 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
EP2482837A4 (en) 2009-09-29 2013-05-22 Joslin Diabetes Center Inc USE OF PROTEIN KINASE C-DELTA (PKCD) INHIBITORS FOR THE TREATMENT OF DIABETES, ADIPOSITAS AND LIVER VARIATION
WO2011109678A1 (en) * 2010-03-05 2011-09-09 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2013025525A1 (en) 2011-08-12 2013-02-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for specific regulation of pyruvate dehydrogenase kinase
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
JP6998657B2 (ja) 2013-09-18 2022-02-04 エピアクシス セラピューティクス プロプライエタリー リミテッド 幹細胞調節ｉｉ
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
MX2018012351A (es) 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
IL271845B2 (en) 2017-07-13 2024-06-01 Michael David Forrest Therapeutic modulators of the reverse mode of atp synthase
CA3082055A1 (en) 2017-11-08 2019-05-16 Epiaxis Therapeutics Pty Ltd Immunogenic compositions and uses therefor
US20230003894A1 (en) * 2019-12-16 2023-01-05 Sony Semiconductor Solutions Corporation Time-of-flight imaging circuitry, time-of-flight imaging system, time-of-flight imaging method
JP7649479B2 (ja) * 2020-03-31 2025-03-21 東レ株式会社 画像解析装置、画像解析装置の制御方法、画像解析システム、及び、画像解析システムの制御方法
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351829A (en) 1980-09-26 1982-09-28 Farmitalia Carlo Erba Spa Use of polypeptides as analgesic drugs
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
US5776685A (en) * 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6218113B1 (en) 1998-02-24 2001-04-17 Incyte Genomics, Inc. Human protein kinase C inhibitor
US6376467B1 (en) 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
DE69934689T2 (de) 1998-07-06 2007-10-25 The Regents Of The University Of California, Oakland Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen
DE69920473T2 (de) * 1998-07-21 2006-02-23 Cytovia, Inc., San Diego Neue fluoreszenzfarbstoffe und ihre anwendung in fluoreszenznachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
US6395306B1 (en) * 1998-09-14 2002-05-28 Pan Pacific Pharmaceuticals, Inc. Bee venom protein and gene encoding same
JP2002525382A (ja) * 1998-09-25 2002-08-13 ザ チルドレンズ メディカル センター コーポレイション プロテインキナーゼの活性を選択的に調節するショートペプチド
GB9905218D0 (en) 1999-03-09 1999-04-28 Univ Glasgow Neurodegenerative disorder related gene
WO2001044497A2 (en) * 1999-12-02 2001-06-21 University Of Dundee Protein kinase regulation
CN1300845A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6496425B1 (en) * 2000-08-21 2002-12-17 Micron Technology, Inc Multiple bit line column redundancy
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US7393835B2 (en) 2002-04-22 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C

Similar Documents

Publication Publication Date Title
JP2005523326A5 (enExample)
CA2482598A1 (en) Peptide inhibitors of protein kinase c
JP2012501973A5 (enExample)
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
FI3642340T3 (fi) Muunneltu l-asparaginaasi
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
TWI455721B (zh) 癌疫苗組合物
NZ602824A (en) Sparc binding peptides and uses thereof
JP2008508859A5 (enExample)
JP2012115277A5 (enExample)
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2013520405A5 (enExample)
JP2011250797A5 (enExample)
WO2012142320A3 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP2016502551A5 (enExample)
JPWO2019156137A5 (enExample)
JP2012529293A5 (enExample)
JP2012102105A5 (enExample)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
NZ606480A (en) Albumin binding peptide-mediated disease targeting
JP2014050390A5 (enExample)
JP2019533722A5 (enExample)